Business
LPLDL® reduces high blood pressure
LPLDL® reduces high blood pressure.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 0633Z OptiBiotix Health PLC 08 January 2020 \n\nOptiBiotix Health Plc\n(\"OptiBiotix\" or the \"Company\")\n \nHuman study shows formulation with LPLDL® reduces high blood pressure\n \nOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. (\"ProBiotix\"), in partnership with Nutrilinea Srl. (\"Nutrilinea\") has completed a successful human study for a new food supplement formulation containing LPLDL® and has shown the product can reduce high blood pressure (hypertension). \nThe study was part of an agreement (RNS: 20 May 2019) with Nutrilinea to fund the development, manufacture, and carrying out of human studies for a new blood pressure product in return for 12 months exclusivity from the date the data was made available from the human study (18 December 2019) for the European market. ProBiotix has exclusivity for the UK and all other markets outside Europe. \nThe three month study of 40 patients was carried out by the Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and showed statistically significant reductions in both systolic, diastolic blood pressure levels, and cholesterol levels. The results of this study are consistent with ProBiotix's initial study conducted at the University of Reading which showed a statistically significant reduction in both blood pressure and cholesterol in volunteers taking LPLDL® (Costabile et al., 2017). \n \nThe European Cardiovascular Society reported in 2016 that the combination of lowering LDL cholesterol and systolic blood pressure has the potential to \"dramatically reduce\" a person's lifetime risk of cardiovascular disease. Hypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases. The fact that it does not have obvious symptoms has led doctors to call hypertension a 'silent killer'. Studies conducted in Europe and in the United States suggest that, under new hypertension guidelines, a large percentage of the adult population m...